{"id":"https://openalex.org/W4361947445","doi":"https://doi.org/10.1158/1078-0432.c.6530619","title":"Data from Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors","display_name":"Data from Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361947445","doi":"https://doi.org/10.1158/1078-0432.c.6530619"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.6530619","doi":"https://doi.org/10.1158/1078-0432.c.6530619","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6530619","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.c.6530619","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5056193789","display_name":"Corey Christian Foster","orcid":"https://orcid.org/0000-0002-3893-834X","observed_orcids":["https://orcid.org/0000-0002-3893-834X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Corey C. Foster","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046031005","display_name":"Gini F. Fleming","orcid":"https://orcid.org/0000-0003-2845-4023","observed_orcids":["https://orcid.org/0000-0003-2845-4023"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gini F. Fleming","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038171309","display_name":"Theodore G Karrison","orcid":"https://orcid.org/0009-0009-8641-5111","observed_orcids":["https://orcid.org/0009-0009-8641-5111"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Theodore G. Karrison","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077771845","display_name":"Chih\u2010Yi Liao","orcid":"https://orcid.org/0000-0002-5114-3162","observed_orcids":["https://orcid.org/0000-0002-5114-3162"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chih-Yi Liao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035557509","display_name":"Ami Vijay Desai","orcid":"https://orcid.org/0000-0001-9658-3156","observed_orcids":["https://orcid.org/0000-0001-9658-3156"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ami V. Desai","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060086956","display_name":"John William Moroney","orcid":"https://orcid.org/0000-0003-4387-5387","observed_orcids":["https://orcid.org/0000-0003-4387-5387"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John W. Moroney","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068268371","display_name":"Mark J. Ratain","orcid":"https://orcid.org/0000-0002-0938-4392","observed_orcids":["https://orcid.org/0000-0002-0938-4392"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark J. Ratain","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005007467","display_name":"Rita Nanda","orcid":"https://orcid.org/0000-0001-5248-0876","observed_orcids":["https://orcid.org/0000-0001-5248-0876"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rita Nanda","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5248-0876","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064525249","display_name":"Blas\u00e9 N. Polite","orcid":"https://orcid.org/0000-0001-8743-8096","observed_orcids":["https://orcid.org/0000-0001-8743-8096"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Blase N. Polite","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113098970","display_name":"Olwen Mary Hahn","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Olwen M. Hahn","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018398274","display_name":"Peter H. O\u2019Donnell","orcid":"https://orcid.org/0000-0003-2650-0049","observed_orcids":["https://orcid.org/0000-0003-2650-0049"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter H. O'Donnell","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063904421","display_name":"Everett E. Vokes","orcid":"https://orcid.org/0000-0002-8645-8068","observed_orcids":["https://orcid.org/0000-0002-8645-8068"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Everett E. Vokes","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8645-8068","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090156519","display_name":"Hedy Lee Kindler","orcid":"https://orcid.org/0000-0002-5450-842X","observed_orcids":["https://orcid.org/0000-0002-5450-842X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hedy L. Kindler","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050168565","display_name":"Robyn D. Hseu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robyn Hseu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071718298","display_name":"Linda A. Janisch","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Linda A. Janisch","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049108815","display_name":"Julia Dai","orcid":"https://orcid.org/0000-0002-3061-6231","observed_orcids":["https://orcid.org/0000-0002-3061-6231"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Julia Dai","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104110119","display_name":"Mark D. Hoffman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark D. Hoffman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054855052","display_name":"Ralph R. Weichselbaum","orcid":"https://orcid.org/0000-0002-5643-8939","observed_orcids":["https://orcid.org/0000-0002-5643-8939"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ralph R. Weichselbaum","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5643-8939","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030967817","display_name":"Sean P. Pitroda","orcid":"https://orcid.org/0000-0003-3056-7991","observed_orcids":["https://orcid.org/0000-0003-3056-7991"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sean P. Pitroda","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055476105","display_name":"Steven J. Chmura","orcid":"https://orcid.org/0000-0001-8851-7108","observed_orcids":["https://orcid.org/0000-0001-8851-7108"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Steven J. Chmura","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5063337705","display_name":"Jason J. Luke","orcid":"https://orcid.org/0000-0002-1182-4908","observed_orcids":["https://orcid.org/0000-0002-1182-4908"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jason J. Luke","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1182-4908","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10358","display_name":"Advanced Radiotherapy Techniques","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/3108","display_name":"Radiation"},"field":{"id":"https://openalex.org/fields/31","display_name":"Physics and Astronomy"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10522","display_name":"Medical Imaging Techniques and Applications","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/stereotactic-body-radiation-therapy","display_name":"stereotactic body radiotherapy","score":0.9980000257492065},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9940000176429749},{"id":"https://openalex.org/keywords/urelumab","display_name":"urelumab","score":0.9620000123977661},{"id":"https://openalex.org/keywords/csf1r-blockade","display_name":"CSF1R blockade","score":0.8960000276565552},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.6840000152587891},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8259999752044678},{"id":"https://openalex.org/keywords/metastasis","display_name":"metastasis","score":0.8970000147819519},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7419999837875366},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.5889999866485596},{"id":"https://openalex.org/keywords/interleukin-8","display_name":"interleukin-8","score":0.597000002861023},{"id":"https://openalex.org/keywords/treatment-efficacy-and-safety","display_name":"treatment efficacy and safety","score":0.5839999914169312},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.43799999356269836},{"id":"https://openalex.org/keywords/lung-cancer","display_name":"lung cancer","score":0.4749999940395355},{"id":"https://openalex.org/keywords/liver-cancer","display_name":"liver cancer","score":0.7289999723434448},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.5149999856948853}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8879640102386475},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.8509735465049744},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6343201398849487},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.5631039142608643},{"id":"https://openalex.org/C2989005","wikidata":"https://www.wikidata.org/wiki/Q214963","display_name":"Nuclear medicine","level":1,"score":0.46621638536453247},{"id":"https://openalex.org/C2780387249","wikidata":"https://www.wikidata.org/wiki/Q973234","display_name":"Radiosurgery","level":3,"score":0.4478243887424469},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.44454264640808105},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.42236340045928955},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3787608742713928},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.3707100450992584},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.3622361123561859},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3211541175842285},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.301460862159729},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.19131097197532654},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.14799100160598755}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.6530619","doi":"https://doi.org/10.1158/1078-0432.c.6530619","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6530619","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.6530619","doi":"https://doi.org/10.1158/1078-0432.c.6530619","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6530619","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3175162150","https://openalex.org/W3094139012","https://openalex.org/W2889613762","https://openalex.org/W3031153849","https://openalex.org/W7204211541","https://openalex.org/W4412552341","https://openalex.org/W3197047635","https://openalex.org/W4417280910","https://openalex.org/W4417516176","https://openalex.org/W2890302782"],"abstract_inverted_index":{"AbstractPurpose:":[0],"CD137":[1],"agonism":[2],"and":[3,11,21,34,65,99,108,123,159,176,197,205,215,251],"CSF1R":[4],"blockade":[5],"augment":[6],"stereotactic":[7],"body":[8],"radiotherapy":[9],"(SBRT)":[10],"anti-programmed":[12],"death-1":[13],"in":[14,144],"preclinical":[15],"models.":[16],"We":[17],"evaluated":[18],"the":[19,72,145],"safety":[20],"efficacy":[22],"of":[23],"SBRT":[24,53,78,233],"with":[25,43,59,75,224,237,248],"nivolumab+urelumab":[26,60,238],"(CD137":[27],"agonist)":[28],"or":[29,61,239],"nivolumab+cabiralizumab":[30,62,240],"(CSF1R":[31],"inhibitor).":[32],"Patients":[33],"Methods:":[35],"This":[36],"phase":[37],"I":[38],"clinical":[39],"trial":[40],"enrolled":[41],"patients":[42,105,113,129,166,223],"advanced":[44,243],"solid":[45,244],"tumors":[46,245],"that":[47],"had":[48,183,188,193,199],"progressed":[49],"on":[50],"standard":[51],"therapies.":[52],"was":[54,71,86],"delivered":[55],"to":[56,234],"1\u20134":[57],"metastases":[58],"given":[63],"concurrently":[64],"following":[66,146],"SBRT.":[67],"Dose-limiting":[68],"toxicity":[69,250],"(DLT)":[70],"primary":[73],"endpoint":[74],"anatomic":[76,147],"location-specific":[77],"doses":[79],"deemed":[80],"safe":[81],"if":[82],"\u226433%":[83],"DLT":[84,133],"frequency":[85],"observed.":[87],"Secondary":[88],"endpoints":[89],"included":[90],"RECISTv1.1":[91],"response,":[92],"progression-free":[93],"survival":[94,97],"(PFS),":[95],"overall":[96,171],"(OS),":[98],"molecular":[100],"correlative":[101],"studies.":[102],"Results:":[103],"Sixty":[104],"were":[106],"enrolled,":[107],"median":[109],"follow-up":[110],"for":[111,169,241],"living":[112],"is":[114,246],"13.8":[115],"months.":[116],"Of":[117,164],"these,":[118],"23":[119,177],"(38%)":[120],"received":[121,126],"SBRT+nivolumab+urelumab":[122],"37":[124],"(62%)":[125],"SBRT+nivolumab+cabiralizumab.":[127],"Seven":[128],"(12%)":[130],"experienced":[131,229],"a":[132,230],"(n":[134],"=":[135,140],"3":[136],"grade":[137,142],"3,":[138],"n":[139],"4":[141],"4)":[143],"cohorts:":[148],"abdominal/pelvic":[149],"(3/17,":[150],"18%),":[151],"liver":[152],"(1/13,":[153],"8%),":[154],"central":[155],"lung":[156,161],"(2/14,":[157],"14%),":[158],"peripheral":[160],"(1/12,":[162],"8%).":[163],"41":[165],"radiographically":[167],"evaluable":[168],"best":[170],"response":[172],"including":[173],"55":[174],"radiated":[175],"unirradiated":[178],"RECIST":[179],"target":[180],"lesions,":[181],"2":[182],"complete":[184],"responses":[185,190],"(5%),":[186],"7":[187],"partial":[189],"(17%),":[191],"12":[192],"stable":[194],"disease":[195],"(29%),":[196],"20":[198],"progression":[200],"(49%).":[201],"Median":[202],"estimated":[203],"PFS":[204],"OS":[206],"are":[207],"3.0":[208],"months":[209,217],"[95%":[210],"confidence":[211],"interval":[212],"(CI),":[213],"2.9\u20134.8]":[214],"17.0":[216],"(95%":[218],"CI,":[219],"6.8\u2013undetermined),":[220],"respectively.":[221],"No":[222],"elevated":[225],"pre-SBRT":[226],"serum":[227],"IL8":[228],"response.":[231],"Conclusions:":[232],"\u22644":[235],"sites":[236],"treating":[242],"feasible":[247],"acceptable":[249],"modest":[252],"antitumor":[253],"activity.":[254],"See":[255],"related":[256],"commentary":[257],"by":[258],"Rodriguez-Ruiz":[259],"et":[260],"al.,":[261],"p.":[262],"5443":[263]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2023-04-05T00:00:00"}